The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development

British Journal of Clinical Pharmacology

Volumn 58, Issue 6, 2004, Pages 601-608

  Walker, D K ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Drug discovery; Drug safety; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CALCIUM ANTAGONIST; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; LOSARTAN; NEW CHEMICAL ENTITY; NEW DRUG; PHOSPHODIESTERASE V INHIBITOR; UK 343 664; UK 84 149; UK 84 189; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG METABOLISM; DRUG MICRODOSE; DRUG SAFETY; ENZYME POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOEPIDEMIOLOGY; PHARMACOGENETICS; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TARGET THERAPEUTIC FREE DRUG CONCENTRATION; TECHNOLOGY; TOXICITY TESTING;

DRUG DESIGN; HUMANS; PHARMACOGENETICS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; TOXICOLOGY;

EID: 10844227564     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02194.x     Document Type: Conference Paper

References (68)

1. Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002; 20 (Suppl. 3): 11-29.
2. Di Masi JA. The value of improving the productivity of the drug development process. Pharmacoeconomics 2002; 20 (Suppl. 3): 1-10.
3. Frantz S, Smith A. New drug approvals for 2002. Nat Rev Drug Discov 2003; 2: 95-6.
4. Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 1988; 25: 387-96.
5. Palmer AM. New horizons in drug metabolism, pharmacokinetics and drug discovery. Drug News Perspect 2003; 16: 57-62.
6. Stewart BH, Chan OH, Lu RH et al. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharm Res 1995; 12: 693-9.
7. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
8. Yee S. In vitro permeability across caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm Res 1997; 14: 763-6.
9. Irvine JD, Takahashi L, Lockhart K et al. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 1999; 88: 28-33.
10. van de Waterbeemd H, Smith DA, Beaumont K, Walker DK. Property-based design: optimisation of drug absorption and pharmacokinetics. J Med Chem 2001; 44: 1313-33.
11. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-79.
12. Obach RS, Baxter JG, Liston TE et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46-58.
13. Lave T, Coassolo P, Reigner B. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 1999; 36: 211-31.
14. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001; 29: 1316-24.
15. Schmider J, von Moltke LL, Shader RI, Harmatz JS, Greenblatt DJ. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. Drug Metab Rev 1999; 31: 545-60.
16. Weaver RJ. Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 2001; 31: 499-538.
17. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 2003; 4: 423-59.
18. Williams JA, Hurst SI, Bauman J et al. Reaction phenotyping in drug discovery: moving forward with confidence? Curr Drug Metab 2003; 4: 527-34.
19. Ings RMJ. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 1990; 20: 1201-31.
20. Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS. The allometric approach for interspecies scaling of pharmacokinetic parameters. Comp Biochem Physiol 1992; 103C: 249-53.
21. Mahmood I, Balian JD. The pharmacokinetic principles behind scaling from preclinical results to phase 1 protocols. Clin Pharmacokinet 1999; 36: 1-11.
22. Mahmood I. Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans. J Clin Pharmacol 2000; 40: 1439-46.
23. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2: 566-80.
24. Greig NH, De Micheli E, Holloway HW et al. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol Scand Supplement 2000; 176: 74-84.
25. Coburn WA. Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 2003; 43: 329-41.
26. Tugwood JD, Hollins LE, Cockerill MJ. Genomics and the search for novel biomarkers in toxicology. Biomarkers 2003; 8: 79-92.
27. Sjoqvist F. Blood binding and drug monitoring. In Protein Binding and Drug Transport, eds Tillement J, Lindenlaub E. Stuttgart: FK Schattauer, 1985; 429-41.
28. Smith DA. Pharmacokinetics and pharmacodynamics in toxicology. Xenobiotica 1997; 27: 513-25.
29. Smith DA, Jones BC, Walker DK. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 1996; 16: 243-66.
30. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. J Am Med Assoc 1990; 264: 2788-90.
31. Crumb W, Cavero I. QT internal prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm Sd Tech Today 1999; 2: 270-80.
32. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001; 57: 185-209.
33. Cavero I, Mestre M, Guillon JM, Crumb W. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing cardiac dysrhythmias. Exp Opin Pharmacother 2000; 1: 947-73.
34. Netzer R, Ebneth A, Bischoff U, Pongs O. Screening lead compounds for QT interval prolongation. Drug Disc Today 2001; 6: 78-84.
35. Leishman DJ, Helliwell R, Wakerall J, Wallis RM. Effects of E-4031, cisapride, terfenadine and terodiline on cardiac repolarisation in canine Purkinje fibre and HERC channels expressed in HEK293 cells. Br J Pharmacol 2000; 133: 130.
36. Webster R, Allan G, Anto-Awuakye K et al. Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. Xenobiotica 2001; 31: 633-50.
37. Webster R, Leishman D, Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 2002; 5: 116-26.
38. Smith DA, Humphrey MJ, Charuel C. Design of toxicokinetic studies. Xenobiotica 1990; 20: 1187-99.
39. Swales K, Plant N, Ayrton A, Hood S, Gibson G. Relative receptor expression is a determinant in xenobiotic-mediated CYP3A induction in rat and human cells. Xenobiotica 2003; 33: 703-16.
40. Zhu W, Song L, Zhang H, Matoney L, LeCluyse E, Van B. Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos 2000; 28: 186-91.
41. Mutlib AE, Gerson RJ, Meunier PC et al. The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 2000; 169: 102-13.
42. Monro A. Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses. J Pharmacokin Biopharm 1994; 22: 41-57.
43. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857-65.
44. Ozdemir V, Shear NH, Kalow W. What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Safety 2001; 24: 75-85.
45. Rodrigues AD, Rushmore TH. Cytochromep450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab 2002; 3: 289-309.
46. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994; 46 (Suppl. 1): 417-24.
47. Strobl GR, von Kruedener S, Stockigt J et al. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modelling and inhibition studies. J Med Chem 1993; 36: 1136-45.
48. Islam SA, Wolf CR, Lennard MS et al. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 1991; 12: 2211-9.
49. Smith DA, Jones BC. Variability in drug response as a factor in drug design. Curr Opin Drug Discov Devel 1999; 2: 33-41.
50. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460-71.
51. Jan MW, Zum Brunnen TL, Kazmi YR. Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. Drug Metabol Drug Interact 2002; 19: 1-11.
52. Crespi CL, Miller VP. The R144C change in CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7: 203-10.
53. Takanashi K, Tainaka H, Kobayashi K et al. CYP2C9 Ile359 and Leu359 variants. Pharmacogenetics 2000; 10: 95-104.
54. Wen SY, Wang H, Sun OJ, Wang SQ. Rapid detection of the known SNPs of CYP2C9 using oligonudeotide microarray. World J Gastroenterol 2003; 9: 1342-6.
55. Sekino K, Kubota T, Okada Y et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59: 589-92.
56. Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
57. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31: 469-97.
58. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003; 4: 397-410.
59. Lappin G, Garner RC. Big physics, small doses, the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2003; 2: 233-40.
60. European Agency for the Evaluation of Medicinal Products (EMEA). Position Paper on Non-clinical Safety Studies to Support Clinical Trials with a Single Microdose. CPMP/SWP/2599/02. London: EMEA, 2003.
61. Kaye B, Garner RC, Mauthe RJ, Freeman SPHT, Turteltaub KW. A preliminary evaluation of accelerator mass spectrometry in the biomedical field. J Pharm Biomed Anal 1997; 16: 541-3.
62. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 2001; 31: 619-32.
63. Sarapa N. Early human microdosing to reduce attrition in clinical drug development. Am Pharmaceut Outsourcing 2003; 1: 1-5.
64. Smith DA, Johnson DE, Park BK. Use of microdosing to probe pharmacokinetics in humans - is it too much for too little? Curr Opin Drug Discov Devel 2003; 6: 39-40.
65. Papac DI, Shahrokh Z. Mass spectrometry innovations in drug discovery and development. Pharm Res 2001; 18: 131-45.
66. Abel S, Beaumont KC, Crespi CL et al. Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica 2001; 31: 665-76.
67. Beaumont K, Harper A, Smith D, Bennett J. The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671. Eur J Pharm Sci 2000; 12: 41-50.
68. Gramatté T, Oertel R, Terhaag B, Kirch W. Direct demonstration of small intestinal secretion and site dependent absorption of the β-blocker talinolol in humans. Clin Pharmacol Ther 1996; 59: 541-9.